Deschloroetizolam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Deschloroetizolam — also known as etizolam-2 — is a synthetic depressant of the thienotriazolodiazepine class. It is the dechlorinated structural analog of Etizolam, with markedly reduced potency.[1] Deschloroetizolam is a positive allosteric modulator of GABA-A receptors, producing its effects by amplifying inhibitory signaling throughout the central nervous system.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, thienodiazepines, Z-drugs (partial) +2 morebenzodiazepines, thienodiazepines, Z-drugs (partial), barbiturates (partial), alcohol (partial) show less
The thienotriazolodiazepine scaffold was first patented by Yoshitomi Pharmaceutical Industries in 1975, but deschloroetizolam was never developed as a pharmaceutical candidate.[3] It emerged in UK illicit drug markets in 2014 as part of the designer benzodiazepine wave driven by scheduling pressure on traditional benzodiazepines.[4] It remains unscheduled in most jurisdictions, though analog-act provisions increasingly apply following etizolam's US Schedule I placement.
Subjective effects include sedation, anxiolysis, muscle relaxation, cognitive suppression, and mild euphoria. The experience is a slow-settling, diffuse calm — less sharp and less rewarding than its parent compound, placing it among the least potent and least euphorigenic designer benzodiazepines.[1] Delusions of sobriety, compulsive redosing, and dose-dependent amnesia are characteristic unsought effects.
Deschloroetizolam carries high abuse liability — including seizure risk on abrupt cessation — and no established lethal dose.[5] The primary acute danger is synergistic respiratory depression when combined with opioids, alcohol, or other depressants, accounting for nearly all designer benzodiazepine fatalities.[6] No formal pharmacological characterization exists — understanding rests on a single human exposure study, in vitro metabolite work, and structural analogy to etizolam.[7]
History[edit]
Discovery
The thienotriazolodiazepine scaffold underlying deschloroetizolam was first described in a 1975 US patent filed by researchers at Yoshitomi Pharmaceutical Industries in Japan.[3] From that program, etizolam — the 2’-chloro-substituted version — was selected for clinical development and approved in Japan in 1983 for anxiety and insomnia.[6] Deschloroetizolam, differing by the absence of that single chlorine atom,[8] was never pursued as a pharmaceutical candidate.
Market emergence
Deschloroetizolam first appeared in UK illicit drug markets in 2014,[4] part of a broader wave of designer benzodiazepines entering new psychoactive substance markets as traditional benzodiazepines faced increasing scheduling pressure.[9] By late 2015 it was confirmed available on research chemical markets,[10] and the Swedish STRIDA project documented at least one acute intoxication case between 2012 and 2016.[11]
Modern status
Deschloroetizolam's relatively low potency — ranking alongside metizolam, nifoxipam, and pyrazolam at the bottom of comparative potency analyses[1] — has limited its commercial persistence relative to more potent compounds like flubromazolam or clonazolam. It appears infrequently in severe intoxication case reports and remains a minor presence in designer benzodiazepine markets.[12]
The name follows standard chemical nomenclature: the prefix "deschloro-" indicates removal of a chlorine atom from the parent compound Etizolam. The alternate designation "Etizolam-2" reflects its position as a structural derivative rather than a distinct pharmaceutical entity. Neither name carries street-level recognition — the compound circulates primarily under its chemical designation in research chemical markets.
Chemistry[edit]
Structural class
Deschloroetizolam belongs to the thienotriazolodiazepine class — a tricyclic scaffold formed by fusion of a thiophene ring, a 1,4-diazepine ring, and a 1,2,4-triazole ring.[8][4] Published forensic toxicology literature consistently uses "thienotriazolodiazepine" rather than "thienodiazepine" to reflect the triazolo ring that distinguishes this family from simpler thienodiazepines.[13]
Structure-activity relationship
Deschloroetizolam is the direct dechlorinated structural analog of etizolam, differing only by the absence of a chlorine atom at the 2’-position of the pendant phenyl ring.[8] This single modification reduces potency — the 2’-chloro substituent in etizolam contributes to enhanced receptor binding, and its removal produces a measurably weaker GABA-A modulator.[1]
Molecular identity
| Molecular formula | C₁₇H₁₆N₄S |
| Molecular weight | 308.4 g/mol |
The tricyclic core consists of a thieno[2,3-e][1,2,4]triazolo[4,3-a][1,4]diazepine ring system bearing a 4-ethyl substituent on the thiophene ring, a 13-methyl group on the triazole ring, and an unsubstituted phenyl ring at the 7-position of the diazepine.
Physical properties
No published data on melting point, solubility, salt forms, or stability under storage conditions exist. As a free base, deschloroetizolam is expected to be a crystalline solid based on structural analogy to etizolam, but this has not been confirmed by published characterization.
Pharmacology[edit]
Mechanism of action
Deschloroetizolam acts as a positive allosteric modulator of the GABA-A, binding at the classical benzodiazepine site located between the α and γ2 subunits.[2] Rather than directly opening the chloride channel, it amplifies the receptor's response to the brain's own GABA — increasing chloride flow into neurons, reducing their excitability, and producing broad central nervous system depression.
The pharmacological output depends on which GABA-A subtypes are engaged: α1-containing receptors drive sedation and sleep; α2- and α3-containing receptors mediate anxiety reduction and muscle relaxation; α5-containing receptors contribute to memory suppression.[2] No published data exist on deschloroetizolam's subunit preferences — these assignments are inferred from the broader benzodiazepine class.
Pharmacokinetics
Human pharmacokinetic data are extremely limited. The only controlled-exposure study documented saliva concentrations after a single 6 mg oral dose taken by a researcher volunteer.[7] Peak saliva concentration occurred approximately 30 minutes after ingestion, followed by rapid initial decline, with traces detectable through the full 18-hour observation window.
Single-volunteer studies documenting half-life data have been referenced in the literature,[6][14] but specific elimination half-life values were not recoverable from available sources. Oral bioavailability, volume of distribution, and protein binding remain uncharacterized in any species.
Metabolism
In vitro studies using human liver microsomes identified at least one monohydroxylated and one dihydroxylated metabolite.[8] The exact positions of hydroxylation on the tricyclic scaffold were not fully determined. Specific metabolic pathways and the influence of genetic variation remain uncharacterized for designer benzodiazepines as a class.[15]
By structural analogy to etizolam, CYP2C19 and CYP3A4 are the likely principal metabolizing enzymes. Clinical studies of etizolam showed that individuals who metabolize CYP2C19 substrates slowly had 2.65-fold higher drug exposure, and adding a CYP3A4 inhibitor increased exposure up to 6.18-fold in these individuals.[16] This vulnerability to genetic variation and drug interactions is expected to apply to deschloroetizolam. inferred
Neuroscience[edit]
Where it acts
Deschloroetizolam enhances inhibitory GABAergic signaling across distributed brain circuits, reducing neuronal excitability broadly. The consequences map onto specific regions: slowed cortical processing produces sedation and cognitive impairment, reduced amygdala reactivity produces anxiolysis, decreased motor neuron excitability produces muscle relaxation, and suppression of ascending arousal circuits produces sleepiness.[2]
The compound's subunit selectivity is unknown. Its effect profile — prominent sedation with moderate anxiety reduction — is consistent with either non-selective or α1-preferring activity at GABA-A receptors.[2]
Tolerance and adaptation
Chronic exposure produces downregulation of GABA-A receptor subunits, particularly α1.[17] This develops within days of continuous dosing. Simultaneously, the brain compensates by increasing excitatory glutamate signaling through NMDA receptors.[5]
This dual shift — reduced inhibition plus heightened excitation — explains both tolerance and the withdrawal. It also explains why tolerance to sedation develops faster than tolerance to anxiety suppression, a pattern observed across the benzodiazepine class.
Key unknowns include whether deschloroetizolam preferentially targets α1-containing (sedative) versus α2/α3-containing (anxiolytic) GABA-A receptors, whether its hydroxylated metabolites[8] retain activity at the receptor, and whether chronic use produces the same pattern of receptor remodeling observed with classical benzodiazepines. No neuroimaging, electrophysiology, or neural network studies have been conducted with this compound.
Subjective Effects[edit]
The experience of deschloroetizolam is defined by gentle, diffuse sedation and anxiety relief with comparatively little reward or cognitive disruption. At lower doses, mild calm and muscle loosening predominate; at higher doses, disinhibition, slurred speech, and anterograde amnesia emerge — though the transition is gradual enough that users frequently misjudge their level of impairment. Set and setting modulate the anxiolytic and disinhibitory dimensions, with stressful contexts amplifying the perceived relief.
Relative to etizolam, the experience is qualitatively similar but quantitatively muted — less euphoria, weaker anxiolysis per milligram, and less amnesia at equivalent doses.[1] It occupies the bottom of the designer benzodiazepine potency spectrum alongside metizolam and nifoxipam, closer in character to low-potency prescription benzodiazepines than to the intensely sedating compounds like flubromazolam or clonazolam that dominate adverse event reports.[12]
Effect Grid
Clear anxiety suppression, moderate sedation, and definite muscle relaxation define the 4–6 mg range. The Ameline et al. 2018 self-experiment at 6 mg — the only controlled human exposure — produced tiredness, dizziness, difficulty speaking, and concentration problems, placing this dose at the upper boundary of the common tier.
Emotional suppression becomes noticeable: affective responses are dampened, and stressors that would normally provoke anxiety feel distant. Disinhibition and delusions of sobriety become relevant safety concerns. Anterograde amnesia risk increases. Driving and complex cognitive tasks are unsafe at this level.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sleep-transition hallucinations
Dizziness · Bodily heaviness · Body high · Breathing alteration · Headache · Nystagmus (eye wobbles) · Dry mouth · Nausea
Headache · Nystagmus (eye wobbles) · Dry mouth · Nausea
Cognitive fatigue · Information processing suppression · Focus suppression · Memory suppression · Language suppression · Memory fragmentation · Suggestibility enhancement · Compulsive redosing urge · Cognitive euphoria · Confusion · Thought disorganization · Amnesia
Memory suppression · Language suppression · Memory fragmentation · Compulsive redosing urge · Cognitive euphoria · Confusion · Thought disorganization · Amnesia
Timeline
Initial anxiolysis and subtle relaxation emerge. A faint softening of tension is perceptible but effects remain subclinical.
Progressive sedation and muscle relaxation build steadily toward full effect. Cognitive slowing becomes apparent.
Maximum sedation, anxiolysis, cognitive impairment, and disinhibition. Delusions of sobriety are most prominent. Amnesia risk is highest.
Gradual reduction of sedation. Residual cognitive impairment and motor coordination effects persist beyond subjective awareness of intoxication.
Lingering drowsiness, possible rebound anxiety, and residual cognitive dulling.
⚠ Do not drive or operate machinery for at least 12 hours after ingestion — residual impairment may persist beyond subjective effect offset.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · thienodiazepines · Z-drugs (partial)
Toxicity
Acute toxicity
No controlled toxicity data — no LD50, no therapeutic index — exist for deschloroetizolam in any species. When taken alone, intrinsic acute toxicity appears low: no fatalities attributable solely to deschloroetizolam have been published.[12] The Swedish STRIDA project documented one confirmed intoxication case between 2012 and 2016, which responded to flumazenil treatment.[11] One additional urine detection was reported from an acute intoxication case, though clinical details for that specific case were not published.[18]
Polydrug lethality
The primary acute lethality risk is synergistic respiratory depression when deschloroetizolam is combined with opioids, alcohol, other benzodiazepines, or GHB. Nearly all deaths associated with designer benzodiazepine misuse occur in polydrug combinations.[6]
Illicitly obtained benzodiazepines have been found to contain opioids as adulterants, creating unintentional polydrug exposure with potentially fatal respiratory depression.[19]
Psychological risks
- Disinhibition: impaired judgment at higher doses, with risk of actions the user would not undertake sober
- Delusions of sobriety: users may believe they are less impaired than they are, promoting redosing and dangerous behavior
- Compulsive redosing: anxiolysis, disinhibition, and amnesia combine so users redose without recalling previous doses
- Amnesia: dose-dependent memory gaps, less pronounced than with flubromazolam or clonazolam[1] but significant at strong doses
- Rebound anxiety: anxiety exceeding baseline levels during offset and for days after use, reinforcing continued use[5]
Prolonged regular use carries risk of depressive symptoms, emotional suppression, and cognitive impairment that may persist into the withdrawal period.[13]
Tolerance and dependence
Tolerance to sedative, sleep-inducing, and muscle-relaxant effects develops within days of continuous use, consistent with the rapid tolerance observed across the benzodiazepine class. Tolerance to anxiolytic effects develops more slowly. inferred
The underlying mechanism involves downregulation of GABA-A subunits[17] and compensatory sensitization of excitatory glutamate signaling.[5] This imbalance drives both escalating tolerance and the withdrawal syndrome.
Physical dependence develops with regular use and carries the full benzodiazepine withdrawal syndrome: rebound effect anxiety and insomnia, tremor, autonomic instability, perceptual disturbances, and in severe cases, life-threatening seizures.[5] Abrupt cessation after prolonged use is medically dangerous. Standard management involves gradual tapering with a long-acting benzodiazepine (e.g. diazepam) under medical supervision.
Psychological dependence is reinforced by the anxiolytic effect — users experiencing baseline or rebound anxiety are strongly motivated to re-administer. Dependence liability is rated high for the benzodiazepine class.[13]
Cross-tolerance exists with all benzodiazepines and thienodiazepines, and is expected with other GABAergic substances including barbiturates, alcohol, and Z-drugs.
Drug interactions
All interaction data are inferred from class-level evidence. No substance-specific interaction studies exist.
The most dangerous combinations involve additive or synergistic depression of the central nervous system and breathing. Opioids represent the highest-lethality pairing: GABA-A enhancement and μ-opioid activation suppress breathing through separate brainstem pathways, and this combination accounts for the majority of benzodiazepine-involved deaths.[6][19]
Alcohol compounds the risk through both direct receptor enhancement and competition for the same liver enzymes. Other GABA-A active substances — other benzodiazepines, barbiturates, GHB/GBL, Z-drugs — produce additive depression at the same receptor.
Drugs that inhibit CYP3A4 (azole antifungals, HIV protease inhibitors, macrolide antibiotics) or CYP2C19 (omeprazole, fluoxetine, fluvoxamine) may substantially increase deschloroetizolam blood levels by slowing its breakdown. In individuals who are genetically slow CYP2C19 metabolizers, adding a CYP3A4 inhibitor produced a 6-fold increase in etizolam exposure.[16] inferred
Stimulants (amphetamines, cocaine, MDMA) mask sedation without reducing respiratory depression, promoting redosing to perceived effect while the underlying danger remains.
Contraindications
No substance-specific contraindication data exist. The following are inferred from the benzodiazepine class:
Absolute contraindications:
- Concurrent use of opioids, alcohol, or other CNS depressants
- Known allergy to thienotriazolodiazepines or benzodiazepines
- Severe respiratory disease — GABA-A enhancement suppresses breathing drive
- Acute narrow-angle glaucoma citation needed
Relative contraindications:
- Genetic CYP2C19 poor metabolizer status — expected elevated blood levels and prolonged effects[16] inferred
- Concurrent CYP3A4 inhibitor therapy
- Myasthenia gravis
- Obstructive sleep apnea
- History of substance use disorder
- Pregnancy citation needed
- Liver impairment — reduced metabolic clearance expected
Harm Reduction[edit]
Forms & Identification
Deschloroetizolam has no pharmaceutical formulations — every sample originates from unregulated synthesis. This means purity, identity, and dose accuracy are never guaranteed. Because designer benzodiazepines are active at milligram-level doses and visually indistinguishable from one another as powders or pressed tablets, an unmarked tablet sold as deschloroetizolam could contain a far more potent compound like flubromazolam or clonazolam, with dramatically different risk profiles.
Reagent testing has limited utility for distinguishing between designer benzodiazepines. Forensic-grade analysis (GC-MS, LC-MS) is the only reliable method for confirming identity. Drug checking services, where available, offer the most accessible path to verification.
Guidelines
- Start with the lowest dose in the threshold range and wait at least 90 minutes before considering redosing — onset can be delayed
- Measure doses with a milligram-precision scale; volumetric dosing from a prepared solution is more accurate than weighing small amounts of powder
- Pre-measure your total intended dose and store remaining material out of reach before dosing — compulsive redosing under the influence is a well-documented pattern with this class
- Do not combine with opioids, alcohol, GHB, or other depressants under any circumstances
- Do not drive or operate machinery; impairment outlasts subjective effects
- Avoid consecutive-day dosing — physical dependence with benzodiazepines can develop within days of regular use
- Inform someone you trust about what you have taken, when, and how much
Set & Setting
The anxiolytic and disinhibitory effects of deschloroetizolam are strongly context-dependent. Using in an unfamiliar or high-stakes environment increases the risk of impaired judgment leading to harmful decisions. A trusted, comfortable setting with no obligations (no driving, no work, no childcare) reduces the probability of disinhibition-related harm.
Having a sober companion present is particularly important with benzodiazepines because delusions of sobriety are a defining feature — the user's own assessment of their impairment is unreliable. A sober observer can intervene if compulsive redosing begins.
Aftercare & integration. Benzodiazepine aftercare centers on managing rebound effects. Anxiety, insomnia, and irritability commonly intensify for one to several days after a single use, and these symptoms can motivate further dosing if not anticipated.
Prioritize sleep hygiene, hydration, and light activity in the days following use. Avoid using other depressants (including alcohol) to manage rebound symptoms, as this extends the cycle of GABAergic disruption. If rebound anxiety is severe or persistent, consult a healthcare provider rather than self-medicating.
Recovery & Support
Benzodiazepine dependence is a medical condition requiring supervised management. Abrupt cessation after regular use risks life-threatening seizures — tapering under medical guidance is essential.
Standard clinical practice involves switching to a long-acting benzodiazepine (typically diazepam) and reducing the dose gradually over weeks to months. The Ashton Manual remains the most widely referenced tapering guide for benzodiazepine withdrawal.
Support resources include the SAMHSA National Helpline (1-800-662-4357, US), Benzo Buddies peer support community, and local addiction medicine services. Cognitive behavioral therapy has demonstrated efficacy for benzodiazepine discontinuation when combined with medical taper.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes slow, shallow, or stops
- Skin or lips turn blue or grey
- Person is unresponsive or cannot be woken
- Seizure activity (jerking movements, loss of consciousness)
These signs distinguish a medical emergency from expected sedation. Heavy drowsiness alone, while concerning, is not the same as respiratory failure.
Immediate steps:
- 1. Call emergency services immediately if breathing is compromised or the person is unresponsive
- 2. Place the person in the recovery position (on their side) to prevent choking if they vomit
- 3. Monitor breathing continuously until help arrives
- 4. Do not induce vomiting
- 5. Do not leave the person alone
What to tell the dispatcher:
- "They took a benzodiazepine-type substance" — name the compound if known
- Approximate amount and time of ingestion
- Any other substances taken (alcohol, opioids)
- Current symptoms: breathing rate, responsiveness, skin color
Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Reversal agent: Flumazenil can reverse benzodiazepine effects and has been used successfully in at least one documented deschloroetizolam intoxication.[11] However, flumazenil is hospital-administered, can precipitate seizures in dependent individuals, and is not available over the counter.
Legal Status[edit]
Deschloroetizolam occupies an ambiguous legal position internationally. It is not specifically scheduled under most national controlled substance frameworks, but falls under blanket new psychoactive substance or structural analog legislation in several jurisdictions. Its parent compound etizolam has faced increasing regulatory action — including permanent US Schedule I placement effective April 2026[20] — which strengthens the legal basis for analog-act prosecution of deschloroetizolam.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not specifically scheduled | Not included in the April 2026 Schedule I placement of five designer benzodiazepines.[20] Likely subject to prosecution under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption, given structural and pharmacological similarity to now-Schedule I etizolam. |
| United States (Alabama) | Schedule I | State-level scheduling effective July 15, 2024.citation needed |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Illegal to produce, supply, or import for human consumption since May 26, 2016.[21] |
| Germany | Controlled (NpSG) | Specifically scheduled under the Neue-psychoaktive-Stoffe-Gesetz as of July 18, 2019; broader NpSG framework in force since November 26, 2016.citation needed |
| Sweden | Hazardous substance (hälsofarlig vara) | Classified since October 15, 2015 — one of the earliest national controls for deschloroetizolam.[21] |
| Russia | Schedule III | Controlled since 2017.citation needed |
| Switzerland | Nationally controlled | Controlled alongside other benzodiazepine derivatives since approximately April 2017.citation needed |
| Canada | Not scheduled | Not listed under the Controlled Drugs and Substances Act. Sale for human consumption without regulatory approval violates the Food and Drugs Act. |
| Australia | Unclear | Etizolam is Schedule 4. Analog provisions may apply to deschloroetizolam, but specific scheduling has not been confirmed by primary sources.citation needed |
Analog act considerations
The US Federal Analogue Act (21 U.S.C. § 813) treats substances "substantially similar" in chemical structure and pharmacological effect to a Schedule I or II controlled substance as controlled when intended for human consumption. With etizolam permanently placed in Schedule I effective April 1, 2026, deschloroetizolam — differing from etizolam by a single chlorine atom and sharing the same mechanism of action — meets the structural similarity threshold for analog-act prosecution. This creates a practical federal prohibition even in the absence of specific scheduling.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]